RxDoctor Payments Data

Stephen Badylak

Lafayette, INNPI 1588037816

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (50.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Triad Life Sciences Inc. accounts for 62.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $581,878 and has fallen 83.3% since, to $97,136 in 2025.

$962,992in general payments, 2019–2025

Across 298 payments — averaging $3231.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Triad Life Sciences Inc.$597K
  • Convatec Inc.$191K
  • Davol Inc.$167K
  • Bard Peripheral Vascular, Inc.$3K
  • Elutia, Inc.$2K
  • BD$1K
  • plus $819 from 3 others
$3,467,127in research payments, 2019–2025

Across 47 payments — averaging $73,769 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Davol Inc.$3.2M
  • Convatec Inc.$244K
  • Elutia, Inc.$12K

What the payments were for

  • Consulting fees$335,97535%
  • Speaking & faculty fees$98,40010%
  • Travel & lodging$40,2804%
  • Food & beverage$7,2071%
  • Other$481,13050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →